Cargando…
Adenovirus‐associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus‐associated virus vector–serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A
BACKGROUND: Current treatment for severe hemophilia A is replacement of deficient factor. Although replacement therapy has improved life expectancy and quality, limitations include frequent infusions and high costs. Gene therapy is a potential alternative that utilizes an adeno‐associated virus (AAV...
Autores principales: | Stanford, Sophia, Pink, Ruth, Creagh, Desmond, Clark, Amanda, Lowe, Gillian, Curry, Nicola, Pasi, John, Perry, David, Fong, Sylvia, Hayes, Gregory, Chandrakumaran, Kandiah, Rangarajan, Savita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462753/ https://www.ncbi.nlm.nih.gov/pubmed/31011710 http://dx.doi.org/10.1002/rth2.12177 |
Ejemplares similares
-
Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A
por: Klamroth, Robert, et al.
Publicado: (2022) -
Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022) -
Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A
por: Kaneda, Makoto, et al.
Publicado: (2021) -
Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands
por: van Balen, Erna C., et al.
Publicado: (2021) -
Seroprevalence to adeno‐associated virus type 6 in people with hemophilia B from a UK adult cohort
por: Boyce, Sara, et al.
Publicado: (2022)